Iotrolan

Summary

Iotrolan (CHEMBL1200555) is an approved unknown (ATC V08AB06).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• ATC class: V08AB06
• Chemistry: 1626.2 Da · C37H48I6N6O18

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200555
Name	Iotrolan
Type	Unknown
Max phase	4
FDA approved	no
PubChem CID	3738
ATC	V08AB06
Molecular formula	C37H48I6N6O18
Molecular weight	1626.2
InChIKey	XUHXFSYUBXNTHU-UHFFFAOYSA-N

SMILES: CN(C1=C(C(=C(C(=C1I)C(=O)NC(CO)C(CO)O)I)C(=O)NC(CO)C(CO)O)I)C(=O)CC(=O)N(C)C2=C(C(=C(C(=C2I)C(=O)NC(CO)C(CO)O)I)C(=O)NC(CO)C(CO)O)I

IUPAC name: 2,4,6-triiodo-5-[methyl-[3-oxo-3-[2,4,6-triiodo-N-methyl-3,5-bis(1,3,4-trihydroxybutan-2-ylcarbamoyl)anilino]propanoyl]amino]-1-N,3-N-bis(1,3,4-trihydroxybutan-2-yl)benzene-1,3-dicarboxamide

Also known as: Iotrol, Iotrolan, Isovist 300, Osmovist, Osmovist 190, Osmovist 240, ZK 39 482, ZK-39482, IOTROLAN

Patent coverage: 818 distinct patent families (2,734 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).